IL226123A - Cest systems that show an independent reaction to the substance concentration - Google Patents

Cest systems that show an independent reaction to the substance concentration

Info

Publication number
IL226123A
IL226123A IL226123A IL22612313A IL226123A IL 226123 A IL226123 A IL 226123A IL 226123 A IL226123 A IL 226123A IL 22612313 A IL22612313 A IL 22612313A IL 226123 A IL226123 A IL 226123A
Authority
IL
Israel
Prior art keywords
systems exhibiting
concentration independent
cest
responsiveness
independent responsiveness
Prior art date
Application number
IL226123A
Other languages
English (en)
Hebrew (he)
Other versions
IL226123A0 (en
Original Assignee
Bracco Imaging Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging Spa filed Critical Bracco Imaging Spa
Publication of IL226123A0 publication Critical patent/IL226123A0/en
Publication of IL226123A publication Critical patent/IL226123A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
IL226123A 2010-11-05 2013-05-02 Cest systems that show an independent reaction to the substance concentration IL226123A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190161A EP2457594A1 (en) 2010-11-05 2010-11-05 Cest systems exhibiting a concentration independent responsiveness
PCT/EP2011/069406 WO2012059576A1 (en) 2010-11-05 2011-11-04 Cest systems exhibiting a concentration independent responsiveness

Publications (2)

Publication Number Publication Date
IL226123A0 IL226123A0 (en) 2013-06-27
IL226123A true IL226123A (en) 2016-02-29

Family

ID=43530158

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226123A IL226123A (en) 2010-11-05 2013-05-02 Cest systems that show an independent reaction to the substance concentration

Country Status (11)

Country Link
US (2) US10232060B2 (enExample)
EP (2) EP2457594A1 (enExample)
JP (2) JP2013542948A (enExample)
KR (1) KR20130138807A (enExample)
CN (1) CN103260652B (enExample)
AU (1) AU2011325112B2 (enExample)
CA (1) CA2816948C (enExample)
IL (1) IL226123A (enExample)
MX (1) MX349239B (enExample)
RU (1) RU2605823C2 (enExample)
WO (1) WO2012059576A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10791989B2 (en) * 2013-04-05 2020-10-06 The Trustees Of The University Of Pennsylvania Magnetic resonance imaging of poly-L-glutamate
KR101653064B1 (ko) * 2014-12-26 2016-09-09 에스티팜 주식회사 가도부트롤의 제조방법
WO2016123446A1 (en) * 2015-01-30 2016-08-04 The Johns Hopkins University Label-free mr imaging of tumor malignancy
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
PL3753929T3 (pl) * 2015-12-10 2023-03-13 Bracco Imaging Spa Dimeryczne środki kontrastowe
CN108369266B (zh) * 2015-12-23 2021-08-06 伯拉考成像股份公司 比率计量的脉冲cest成像
RU2755181C2 (ru) 2016-11-28 2021-09-14 Байер Фарма Акциенгезельшафт Новые хелатные соединения гадолиния с высокой релаксивностью для применения в магнитно-резонансной визуализации
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
CN108047151B (zh) * 2018-01-03 2020-08-04 广州康瑞泰药业有限公司 一种高收率钆布醇的制备方法
IL321215B2 (en) 2018-11-23 2026-05-01 Bayer Ag Contrast media formulation and process for its preparation
US12226494B2 (en) 2018-12-18 2025-02-18 Bracco Imaging S.P.A. Pharmaceutical compositions comprising Gd-complexes and polyarylene additives
US20200397924A1 (en) * 2019-01-28 2020-12-24 Hubei Tianshu Pharmaceutical Co., Ltd Preparation method of intermediate of gadolinium-based ionic contrast agent and use thereof
US12529739B2 (en) * 2022-07-26 2026-01-20 Canon Medical Systems Corporation pH calculating apparatus, magnetic resonance imaging apparatus, and pH calculating method
CN120609858B (zh) * 2025-05-30 2026-07-31 中国科学院精密测量科学与技术创新研究院 镧系金属配合物作为31p cest高场造影剂在识别atp中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4009119A1 (de) 1990-03-19 1991-09-26 Schering Ag 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
GB9504910D0 (en) 1995-03-10 1995-04-26 Nycomed Imaging As Compounds
AU4656400A (en) 1999-04-21 2000-11-17 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Method for enhancing contrast produced by mri
US6875419B2 (en) * 2000-11-20 2005-04-05 Board Of Regents The University Of Texas System Paramagnetic metal ion-based macrocyclic magnetization transfer contrast agents and method of use
EP1331012A1 (en) * 2002-01-29 2003-07-30 BRACCO IMAGING S.p.A. Responsive paramagnetic MRI contrast agents
EP1466629A1 (en) * 2003-04-11 2004-10-13 BRACCO IMAGING S.p.A. Adducts between magnetic resonance shift reagents and substrates containing exchangeable protons for "CEST" applications
WO2006032705A2 (en) 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
EP2035044B1 (en) * 2006-06-09 2013-10-16 Koninklijke Philips N.V. Elimination of contrast agent concentration dependency in mri
JP2011505896A (ja) * 2007-12-07 2011-03-03 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 画像誘導送達のための高分子薬剤キャリア
EP2067485A1 (en) * 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement

Also Published As

Publication number Publication date
EP2635311B1 (en) 2017-08-16
EP2635311A1 (en) 2013-09-11
US20190209713A1 (en) 2019-07-11
EP2457594A1 (en) 2012-05-30
CA2816948C (en) 2016-04-05
IL226123A0 (en) 2013-06-27
MX2013004825A (es) 2013-06-03
JP2013542948A (ja) 2013-11-28
US20130195768A1 (en) 2013-08-01
US10328162B1 (en) 2019-06-25
CA2816948A1 (en) 2012-05-10
US10232060B2 (en) 2019-03-19
AU2011325112B2 (en) 2016-03-31
JP2017078080A (ja) 2017-04-27
WO2012059576A1 (en) 2012-05-10
KR20130138807A (ko) 2013-12-19
CN103260652B (zh) 2016-10-12
AU2011325112A1 (en) 2013-05-02
RU2013125778A (ru) 2014-12-10
CN103260652A (zh) 2013-08-21
JP6542748B2 (ja) 2019-07-10
RU2605823C2 (ru) 2016-12-27
MX349239B (es) 2017-07-18

Similar Documents

Publication Publication Date Title
IL226123A0 (en) cest systems that show a reaction independent of the concentration of the substance
SG10201510760WA (en) Expression systems
EP2638405A4 (en) EXTENDED LOCATION SYSTEM
GB201007196D0 (en) Gas-to-liquid technology
PL2585569T3 (pl) Systemy zapachowe
ZA201207343B (en) Fastener
PL2627917T3 (pl) Łącznik z trzpieniem
GB2477554B (en) Control systems
TWM386518U (en) Linear regulator
EP2636037A4 (en) MAGNETIC RAILWAY SYSTEMS
TWM402991U (en) LED seal structure
GB2480320B (en) Calendar
GB201119674D0 (en) Fastener
EP2623577A4 (en) ADHESIVE
GB201020498D0 (en) Spool valve
GB201015490D0 (en) fastener systems
GB201002076D0 (en) Anchoring systems
GB2478612B (en) Access systems
AU4804P (en) MOUTERE Rubus ideaus
GB201107393D0 (en) Self adhesive catch member
GB201000112D0 (en) Fencing systems
GB201016074D0 (en) Adhesive tape
GB201016402D0 (en) Slot assembly
GB201012742D0 (en) Alarm systems
GB201013322D0 (en) Solenoid-operated valve

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed